Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Sarina A. Piha‐Paul et al.|Nature Medicine|2023Cited by 372
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A. Yap, Johann S. de Bono|CA A Cancer Journal for Clinicians|2011Cited by 209
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Douglas S. Barker et al.|Clinical Cancer Research|2011Cited by 168
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I StudyTimothy A. Yap, Simon J. Hollingsworth|Clinical Cancer Research|2021Cited by 134
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Rebecca Kristeleit et al.|Cancer Discovery|2020Cited by 134